Levilactobacillus brevis
Levilactobacillus brevis (formerly Lactobacillus brevis, species-level entry) is a lactic acid bacterium associated with fermented foods and studied for two principal properties: GABA (gamma-aminobutyric acid) production and antioxidant activity. GABA production during fermentation of plant-based substrates has been documented in multiple in vitro studies of various L. brevis strains, and antioxidant activity has been examined in an animal study of an L. brevis isolate. The species has also been investigated in vitro for antiviral activity against herpes simplex virus type 2 and for competitive exclusion of food pathogens. Evidence is largely strain-specific and in vitro or animal-based; human clinical evidence for this species-level entry is not available in the linked literature. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 45 body-system-tagged papers that concern each system. Research coverage, not measured effect.
+4 more systems
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 16 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+1 more symptoms
Strains of this species
4 strains of Levilactobacillus brevis in the index, with 90 linked papers between them.
Levilactobacillus brevis CD2
Levilactobacillus brevis CD2 (formerly Lactobacillus brevis CD2) has a focused research record centered on oral health applications, particularly the prevention and management of oral mucositis — painful inflammation of …
Levilactobacillus brevis KB290
Levilactobacillus brevis KB290 (formerly Lactobacillus brevis KB290) is a Japanese probiotic strain with a sequenced genome and a body of human and animal research.
Levilactobacillus brevis SBC8803
Levilactobacillus brevis SBC8803 (also marketed as SBL88) has an unusual research profile centered on heat-killed rather than live cells, a preparation sometimes called a paraprobiotic.
Levilactobacillus brevis GABA100
Levilactobacillus brevis GABA100 is a strain selected for its capacity to produce gamma-aminobutyric acid (GABA), a naturally occurring amino acid with inhibitory signaling roles in the nervous system.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
146 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 21741230 →Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study· European Journal of Cancer · 2011
-
[2]
PMID 17577323 →Anti‐inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease· Oral Diseases · 2007